Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ANKRD62P1-PARP4P3 readthrough, transcribed pseudogene is a natural readthrough locus that joins two annotated pseudogenes: ankyrin repeat domain 62 pseudogene 1 (ANKRD62P1) and poly(ADP-ribose) polymerase family member 4 pseudogene 3 (PARP4P3). This region is classified as a pseudogene and is transcribed, but the resulting RNA is unlikely to encode a functional protein product. Neither parent pseudogene, nor the readthrough transcript, has a curated, protein-coding function, and there is no evidence it acts as a canonical therapeutic target such as a receptor, enzyme, transporter, or regulatory protein[1][6]. Pseudogenes generally may have regulatory or evolutionary roles at the RNA level, but for this specific readthrough, no defined biological or pathological function has been described[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ANKRD62P1-PARP4P3 readthrough, transcribed pseudogene (ANKRD62P1-PARP4P3).